A Phase 2 open-label trial of ATI-50002 Topical for the treatment of Alopecia Areata (AA).
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2018
At a glance
- Drugs ATI 502 (Primary)
- Indications Alopecia areata
- Focus Therapeutic Use
- 03 Aug 2018 According to an Aclaris Therapeutics media release, interim data from this trial has been presented in the company media release.
- 12 Mar 2018 According to an Aclaris Therapeutics media release, data is expected to be available in the mid-2018.
- 07 Nov 2017 Status changed from planning to recruiting, according to an Aclaris Therapeutics media release.